Is MRNA or MGX more profitable?

Moderna has a net margin of -141.43% compared to Metagenomi's net margin of -384.61%. Moderna's return on equity of -28.30% beat Metagenomi's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Metagenomi -384.61% -51.23% -36.62%

Do analysts rate MENS or MGX?

Metagenomi has a consensus target price of $7.00, suggesting a potential upside of 476.13%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts clearly believe Metagenomi is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Metagenomi 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has higher earnings and valuation, MENS or MGX?

Jyong Biotech has higher earnings, but lower revenue than Metagenomi. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Metagenomi $25.21M 1.81 -$87.87M -$2.30 N/A

Metagenomi (MGX) Competitors

$1.22 +0.01 (+0.41%)

As of 02:50 PM Eastern

Compare

MGX vs. MRNA, PRQR, VYGR, MENS, and LENZ

Should you buy Metagenomi stock or one of its competitors? MarketBeat compares Metagenomi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Metagenomi include Moderna (MRNA), ProQR Therapeutics (PRQR), Voyager Therapeutics (VYGR), Jyong Biotech (MENS), and LENZ Therapeutics (LENZ).

How does Metagenomi compare to Moderna?

Moderna (NASDAQ:MRNA) and Metagenomi (NASDAQ:MGX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

75.3% of Moderna shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 12.5% of Metagenomi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Moderna presently has a consensus price target of $42.13, indicating a potential downside of 26.20%. Metagenomi has a consensus price target of $7.00, indicating a potential upside of 476.13%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	1.88
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Metagenomi has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	11.65	-$2.82B	-$7.99	N/A
Metagenomi	$25.21M	1.81	-$87.87M	-$2.30	N/A

Moderna has a net margin of -141.43% compared to Metagenomi's net margin of -384.61%. Moderna's return on equity of -28.30% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Metagenomi	-384.61%	-51.23%	-36.62%

Moderna has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

In the previous week, Moderna had 52 more articles in the media than Metagenomi. MarketBeat recorded 52 mentions for Moderna and 0 mentions for Metagenomi. Moderna's average media sentiment score of 0.46 beat Metagenomi's score of 0.00 indicating that Moderna is being referred to more favorably in the media.

Company	Overall Sentiment
Moderna	Neutral
Metagenomi	Neutral

Summary

Moderna beats Metagenomi on 9 of the 16 factors compared between the two stocks.

How does Metagenomi compare to ProQR Therapeutics?

Metagenomi (NASDAQ:MGX) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

32.7% of ProQR Therapeutics shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ProQR Therapeutics has lower revenue, but higher earnings than Metagenomi. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.81	-$87.87M	-$2.30	N/A
ProQR Therapeutics	$17.99M	10.63	-$47.73M	-$0.50	N/A

In the previous week, ProQR Therapeutics had 5 more articles in the media than Metagenomi. MarketBeat recorded 5 mentions for ProQR Therapeutics and 0 mentions for Metagenomi. ProQR Therapeutics' average media sentiment score of 1.55 beat Metagenomi's score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Metagenomi	Neutral
ProQR Therapeutics	Very Positive

Metagenomi has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market.

Metagenomi presently has a consensus price target of $7.00, indicating a potential upside of 476.13%. ProQR Therapeutics has a consensus price target of $7.33, indicating a potential upside of 304.04%. Given Metagenomi's stronger consensus rating and higher possible upside, research analysts clearly believe Metagenomi is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

ProQR Therapeutics has a net margin of -331.33% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

Summary

Metagenomi beats ProQR Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Metagenomi compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Voyager Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 434.85%. Metagenomi has a consensus price target of $7.00, suggesting a potential upside of 476.13%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts clearly believe Metagenomi is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

48.0% of Voyager Therapeutics shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by company insiders. Comparatively, 12.5% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Voyager Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Voyager Therapeutics has a net margin of -319.61% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
Metagenomi	-384.61%	-51.23%	-36.62%

In the previous week, Voyager Therapeutics had 3 more articles in the media than Metagenomi. MarketBeat recorded 3 mentions for Voyager Therapeutics and 0 mentions for Metagenomi. Voyager Therapeutics' average media sentiment score of 0.00 equaled Metagenomi'saverage media sentiment score.

Company	Overall Sentiment
Voyager Therapeutics	Neutral
Metagenomi	Neutral

Metagenomi has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	4.62	-$119.72M	-$1.97	N/A
Metagenomi	$25.21M	1.81	-$87.87M	-$2.30	N/A

Summary

Voyager Therapeutics beats Metagenomi on 8 of the 15 factors compared between the two stocks.

How does Metagenomi compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Jyong Biotech has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Jyong Biotech has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Jyong Biotech's return on equity of 0.00% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Metagenomi	-384.61%	-51.23%	-36.62%

Metagenomi has a consensus target price of $7.00, suggesting a potential upside of 476.13%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts clearly believe Metagenomi is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Jyong Biotech has higher earnings, but lower revenue than Metagenomi.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Metagenomi	$25.21M	1.81	-$87.87M	-$2.30	N/A

In the previous week, Jyong Biotech had 1 more articles in the media than Metagenomi. MarketBeat recorded 1 mentions for Jyong Biotech and 0 mentions for Metagenomi. Jyong Biotech's average media sentiment score of 0.59 beat Metagenomi's score of 0.00 indicating that Jyong Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Jyong Biotech	Positive
Metagenomi	Neutral

Summary

Jyong Biotech beats Metagenomi on 7 of the 12 factors compared between the two stocks.

How does Metagenomi compare to LENZ Therapeutics?

Metagenomi (NASDAQ:MGX) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

54.3% of LENZ Therapeutics shares are held by institutional investors. 12.5% of Metagenomi shares are held by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Metagenomi has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

Metagenomi has a net margin of -384.61% compared to LENZ Therapeutics' net margin of -519.30%. LENZ Therapeutics' return on equity of -46.82% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

LENZ Therapeutics has lower revenue, but higher earnings than Metagenomi. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.81	-$87.87M	-$2.30	N/A
LENZ Therapeutics	$19.09M	8.17	-$82.13M	-$3.60	N/A

Metagenomi presently has a consensus target price of $7.00, suggesting a potential upside of 476.13%. LENZ Therapeutics has a consensus target price of $29.80, suggesting a potential upside of 498.99%. Given LENZ Therapeutics' higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
LENZ Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, LENZ Therapeutics had 2 more articles in the media than Metagenomi. MarketBeat recorded 2 mentions for LENZ Therapeutics and 0 mentions for Metagenomi. LENZ Therapeutics' average media sentiment score of 1.34 beat Metagenomi's score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Metagenomi	Neutral
LENZ Therapeutics	Positive

Summary

Metagenomi beats LENZ Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Metagenomi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGX vs. The Competition

Export

Metric	Metagenomi	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$45.75M	$3.54B	$6.80B	$13.01B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-0.53	7.36	279.98	25.51
Price / Sales	1.81	1,272.68	649.35	116.02
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	0.29	17.18	11.15	6.35
Net Income	-$87.87M	-$12.52M	$3.48B	$347.60M
7 Day Performance	0.41%	2.48%	2.51%	3.14%
1 Month Performance	-3.57%	-5.41%	-2.78%	-2.08%
1 Year Performance	-47.17%	51.14%	64.32%	21.27%

Metagenomi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGX Metagenomi	3.0988 of 5 stars	$1.22 +0.4%	$7.00 +476.1%	-46.2%	$45.75M	$25.21M	N/A	236	Upcoming Earnings
MRNA Moderna	1.4943 of 5 stars	$54.07 -2.8%	$40.00 -26.0%	+99.8%	$21.32B	$2.20B	N/A	4,700	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Up
PRQR ProQR Therapeutics	4.2771 of 5 stars	$1.72 -0.3%	$7.33 +325.4%	-17.8%	$180.70M	$13.42M	N/A	180	News Coverage Positive News Upcoming Earnings Gap Up
VYGR Voyager Therapeutics	2.135 of 5 stars	$2.99 -3.1%	$16.50 +451.1%	+1.4%	$180.35M	$40.37M	N/A	100	News Coverage Upcoming Earnings
MENS Jyong Biotech	N/A	$2.34 -3.9%	N/A	-89.5%	$179.36M	N/A	N/A	31

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGX) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Metagenomi (MGX) Competitors

MGX vs. MRNA, PRQR, VYGR, MENS, and LENZ

How does Metagenomi compare to Moderna?

Summary

How does Metagenomi compare to ProQR Therapeutics?

Summary

How does Metagenomi compare to Voyager Therapeutics?

Summary

How does Metagenomi compare to Jyong Biotech?

Summary

How does Metagenomi compare to LENZ Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX vs. The Competition

Metagenomi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Metagenomi (MGX) Competitors

MGX vs. MRNA, PRQR, VYGR, MENS, and LENZ

How does Metagenomi compare to Moderna?

Do insiders & institutionals believe in MRNA or MGX?

Do analysts rate MRNA or MGX?

Which has better earnings and valuation, MRNA or MGX?

Is MRNA or MGX more profitable?

Which has more volatility & risk, MRNA or MGX?

Does the media refer more to MRNA or MGX?

Summary

How does Metagenomi compare to ProQR Therapeutics?

Do insiders & institutionals believe in MGX or PRQR?

Which has preferable valuation & earnings, MGX or PRQR?

Does the media favor MGX or PRQR?

Which has more volatility & risk, MGX or PRQR?

Do analysts recommend MGX or PRQR?

Is MGX or PRQR more profitable?

Summary

How does Metagenomi compare to Voyager Therapeutics?

Do analysts recommend VYGR or MGX?

Do institutionals & insiders hold more shares of VYGR or MGX?

Which has more risk & volatility, VYGR or MGX?

Is VYGR or MGX more profitable?

Does the media favor VYGR or MGX?

Which has preferable valuation and earnings, VYGR or MGX?

Summary

How does Metagenomi compare to Jyong Biotech?

Which has more volatility & risk, MENS or MGX?

Is MENS or MGX more profitable?

Do analysts rate MENS or MGX?

Which has higher earnings and valuation, MENS or MGX?

Does the media prefer MENS or MGX?

Summary

How does Metagenomi compare to LENZ Therapeutics?

Do insiders & institutionals believe in MGX or LENZ?

Which has more risk & volatility, MGX or LENZ?

Is MGX or LENZ more profitable?

Which has better earnings & valuation, MGX or LENZ?

Do analysts prefer MGX or LENZ?

Does the media refer more to MGX or LENZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX vs. The Competition

Metagenomi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools